Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: A phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma

Clinical Colorectal Cancer

Volumn 6, Issue 7, 2007, Pages 536-538

  Venook, Alan P ^a,b   Blanke, Charles D ^c,d   Niedzwiecki, Donna ^a,e   Lenz, Heinz Josef ^c,f   Taylor, John R ^a   Hollis, Donna R ^a,e   Sutherland, Susan ^a,e   Goldberg, Richard M ^a,g  

^a Cancer and Leukemia Group B   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Southwest Oncology Group   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e DUKE UNIVERSITY   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bevacizumab; Cetuximab; FOLFIRI; FOLFOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADJUVANT THERAPY; ARTERY THROMBOSIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLD SENSITIVITY; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ACTIVITY; DRUG ANTAGONISM; HAIR LOSS; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MEDICAL SOCIETY; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PROTEINURIA; RASH; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

EID: 34250330400     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.021     Document Type: Article

References (14)

1. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-1214.
2. Venook AP. Colorectal metastases confined to the liver: a unique opportunity? Semin Oncol 2003; 30:34-39.
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
4. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-4875.
5. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
7. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(16 suppl):1ls (Abstract #2).
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
9. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
10. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: the Annual Meeting of the American Association for Cancer Research; April 1-5, 2006; Washington, DC; Abstract #CP-1.
11. Saltz LB, Lenz H, Hochster H, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2005; 23(16 suppl):248s (Abstract #3508).
12. Amgen discontinues Vectibix™ treatment in PACCE trial evaluating Vectibix™ as part of triple combination regimen: preliminary pre-planned interim analysis shows negative effect on progression-free survival [press release]. Amgen, Inc; March 22, 2007.
13. Saltz LB, Meropol NJ, Loehrer, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
14. Peeters M, Van Cutsem E, Hecht J, et al. Efficacy and safety of panitumumab across five clinical studies in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium; Orlando, FL; January 19-21, 2007. Abstract #336.